Sleeper, L.A., Minich, L.L., McCrindle, B.M., Li, J.S., Mason, W., Colan, S.D., Atz, A.M., Printz, B.F., Baker, A., Vetter, V.L. and Newburger, J.W. (2011) Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. Journal of Pediatrics, 158, 831-835. doi:10.1016/j.jpeds.2010.10.031

has been cited by the following article:

• TITLE: Antimicrobial therapy using sulfamethoxazole trimethoprim for Kawasaki disease patients unresponsive to intravenous immunoglobulin

  AUTHORS: Satoru Nagata, Yuichiro Yamashiro, Makoto Fujimori, Yukihide Chiba, Yoshikazu Ohtsuka, Toshiaki Shimizu

  KEYWORDS: Antimicrobial Therapy; Intravenous Immunoglobulin Resistance; Kawasaki Disease; Sulfamethoxazole Trimethoprim

  JOURNAL NAME: Open Journal of Pediatrics, Vol.1 No.3, September 27, 2011

  ABSTRACT: Our previous study suggested that the production of superantigens and heat-shock protein 60 by small intestinal bacteria might play a role in Kawasaki disease (KD). We demonstrated that they were all resistant to commonly used antibiotics, except for sulamethoxazole trimethoprim (SMX-TMP). We used SMX-TMP for 7 cases of KD that were unresponsive to intravenous immunoglobulin (IVIG) and studied the antipyretic potency of this treatment. In 6 out of the 7 cases, we demonstrated that antipyretic potency was observed without side effects within 2 days of the initial administration. Antimicrobial therapy using SMX-TMP might represent a novel strategy for cases of KD that are unresponsive to IVIG.